Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

Example Citation: Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)

Active as of 2022-01-10

Generated Narrative: Citation

Resource Citation "58" Version "24" Updated "2023-12-06 00:56:00+0000"

StructureDefinition Work Group: cds

url: https://fevir.net/resources/Citation/58

identifier: FEvIR Object Identifier: 58

version: 1.0.0-ballot

title: Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)

status: active

date: 2022-01-10 13:29:15+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

-CodeValue[x]
*FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')FHIR Resource (Citation Artifact Classifier#fhir-resource)

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Brian S. Alper:

Summaries

-StyleText
*Computable Publishing (Citation Summary Style#comppub)14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) [FHIR Resource], version 4. Contributors: Brian S. Alper, Joanne Dehnbostel, Khalid Shahin [Authors]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 55. Created December 17, 2020. Revised December 21, 2020. Accessed March 13, 2021. Available at: https://fevir.net/resources/Evidence/55. Computable resource at: https://fevir.net/resources/Evidence/55.

RelatedArtifacts

-TypeResourceReference
*derived-fromhttps://fevir.net/resources/Evidence/55 "Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY"

citedArtifact

identifier: FEvIR Object Identifier: 55

dateAccessed: 2021-03-13

Versions

-Value
*4

StatusDates

-ActivityActualPeriod
*Created (Cited Artifact Status Type#created)true?? --> 2020-12-17

Titles

-TypeLanguageText
*Primary title (Title Type#primary)English (Tags for the Identification of Languages[4.0.1]#en)14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY).

Abstracts

-TypeLanguageTextCopyright
*Primary human use (Cited Artifact Abstract Type#primary-human-use)English (Tags for the Identification of Languages#en)COVID-19 pneumonia remdesivir vs. placebo 14-day mortality (779 events among 6,744 participants, 3 randomized trials)\nRisk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect analysis\nRisk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects analysishttps://creativecommons.org/licenses/by-nc-sa/4.0/

publicationForm

PublishedIns

-TypeTitlePublisherPublisherLocation
*Database (Published In Type#D019991)Fast Evidence Interoperability Resources (FEvIR) Platform: Computable Publishing LLCIpswich, MA, USA

lastRevisionDate: 2020-12-21

language: English (Tags for the Identification of Languages[4.0.1]#en)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

WebLocations

-ClassifierUrl
*JSON (Artifact Url Classifier#json), Computable resource (Artifact Url Classifier#computable-resource)14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)

classification

type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)

classifier: FHIR Resource (Citation Artifact Classifier#fhir-resource)

classification

type: FHIR Resource (Citation Artifact Classifier#fhir-resource)

classifier: Evidence (All FHIR Types#Evidence)

classification

type: keyword major topic (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")

classifier: remdesivir (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text"), COVID-19 (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text"), pharmaceutical treatment (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")

contributorship

complete: true

entry

contributor:

identifier: id: 0000-0003-4300-4928

name: Brian S. Alper

telecom: balper@computablepublishing.com

forenameInitials: BS

affiliation: : Computable Publishing LLC

contributionType: Conceptualization (Artifact Contribution Type#conceptualization), Data curation (Artifact Contribution Type#data-curation), Supervision (Artifact Contribution Type#supervision)

role: Author/Creator (Contributor Role#author)

correspondingContact: true

entry

contributor:

name: Joanne Dehnbostel

telecom: jdehnbostel@computablepublishing.com

forenameInitials: J

affiliation: : Computable Publishing LLC

contributionType: Formal analysis (Artifact Contribution Type#formal-analysis), Data curation (Artifact Contribution Type#data-curation)

role: Author/Creator (Contributor Role#author)

correspondingContact: false

entry

contributor:

name: Khalid Shahin

telecom: kshahin@computablepublishing.com

forenameInitials: K

affiliation: : Computable Publishing LLC

contributionType: Software (Artifact Contribution Type#software)

role: Author/Creator (Contributor Role#author)

correspondingContact: false


Generated Narrative: Practitioner #contributor0

identifier: id: 0000-0003-4300-4928

name: Brian S. Alper

telecom: balper@computablepublishing.com


Generated Narrative: Practitioner #contributor1

name: Joanne Dehnbostel

telecom: jdehnbostel@computablepublishing.com


Generated Narrative: Practitioner #contributor2

name: Khalid Shahin

telecom: kshahin@computablepublishing.com